Loading clinical trials...
Loading clinical trials...
A Phase 1/2 Study of FOG-001 in Participants With Locally Advanced or Metastatic Solid Tumors
Conditions
Interventions
FOG-001
mFOLFOX-6
+4 more
Locations
25
United States
Honor Health
Scottsdale, Arizona, United States
Arizona Cancer Center at University of Arizona
Tucson, Arizona, United States
University of California, Los Angeles (UCLA)
Los Angeles, California, United States
Stanford Cancer Institute, Stanford University
Palo Alto, California, United States
University of California San Francisco, Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States
Sarcoma Oncology Center
Santa Monica, California, United States
Start Date
May 23, 2023
Primary Completion Date
April 1, 2027
Completion Date
August 31, 2027
Last Updated
April 23, 2026
NCT04570423
NCT06132828
NCT04541381
NCT07489378
NCT05671510
NCT06043817
Lead Sponsor
Parabilis Medicines, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions